Carolyn Bolton Moore, Kristin Baltrusaitis, Edmund V Capparelli, Elizabeth D Lowenthal, Dwight E Yin, John H Moye, Christiana Smith, Michael Whitton, Conn M Harrington, Herta Crauwels, Rodica Van Solingen-Ristea, Mark A Marzinke, Barbara Heckman, Andi Ace, Shawn Ward, Kyle Whitson, Jenny Huang, S Y Amy Cheung, Brookie M Best, Ellen Townley, Allison Agwu, Pradthana Ounchanum, Sisinyana Ruth Mathiba, Linda Aurpibul, Violet Korutaro, Gaerolwe Masheto, Faeezah Patel, Evette Moodley, Aditya H Gaur, Avy Violari, Maxensia Owor, Kulkanya Chokephaibulkit, Andres Camacho-Gonzalez, Mary Paul, Samantha Fry, Jennifer Jao, Charles Mitchell, Sara Zabih, Veerle Van Eygen, Kati Vandermeulen, Ann Buchanan, Yu-Wei Lin, Kelong Han, Jon Collins, Chelsea Stotz, Rachel Scheckter, Sarah Buisson
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Retrospective cohort study of predictors of loss to follow up among adolescents and young adults living with HIV on ART in Dar es Salaam, Tanzania, 2015-2019
10.1186/s12879-025-11157-1 · 2025
High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care
10.1097/qad.0000000000000054 · 2014
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
10.1016/s2352-3018(20)30340-4 · 2021
Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
10.1097/qad.0000000000003025 · 2022
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
10.1038/s41591-025-04041-7 · 2026
10.1016/s2352-3018(23)00300-4
10.1016/s2352-3018(23)00300-4 · 2024
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
10.1016/s2352-3018(24)00344-8 · 2025
10.1016/s2352-3018(23)00301-6
10.1016/s2352-3018(23)00301-6 · 2024
Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
10.1016/s2352-3018(25)00241-3 · 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
10.1016/s2352-3018(25)00242-5 · 2026
Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine
10.1093/cid/ciae579 · 2025
Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort
10.1007/s40121-023-00890-2 · 2023
Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results
10.1093/jac/dkae308 · 2024
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
2023
Efficacy and safety of cabotegravir-rilpivirine in PLWH: a real-world study
10.3390/v17111417 · 2025
Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the Injectable Antiretroviral Therapy Feasibility Study (JABS)
10.1111/hiv.13647 · 2024
Experience of treatment with long-acting injectable cabotegravir/rilpivirine (LA iCAB/RPV) in viremic young patients with perinatally acquired HIV with adherence challenges: a five-case series
10.1016/j.ijid.2025.108104 · 2025
Off-label use of long-acting injectable antiretroviral therapy: a single center retrospective review of youth living with HIV with detectable HIV RNA starting injectable therapy
10.1093/jpids/piae033 · 2024
Efficacy, safety and retention in care among adolescents and youth with HIV on long-acting injectable cabotegravir/rilpivirine treatment: real-world observational cohort outcomes
10.1097/inf.0000000000004742 · 2025
Long-acting injectable antiretroviral therapy in South African adolescents and young adults—week 48 results from the AFINAty Study
10.1097/qai.0000000000003973 · 2026
The Faces Pain Scale—revised: toward a common metric in pediatric pain measurement
10.1016/s0304-3959(01)00314-1 · 2001
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
10.1016/s2352-3018(20)30106-5 · 2020
Development and validation of a liquid chromatographic–tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue
10.1016/j.jpba.2016.08.016 · 2016
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
10.1016/s2352-3018(21)00185-5 · 2021
Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters
10.1093/cid/ciae475 · 2025
Transient viremia among people with HIV receiving injectable cabotegravir plus rilpivirine
10.1089/aid.2024.0083 · 2025
Extrapolation of adult data and other data in pediatric drug-development programs
10.1542/peds.2010-3487 · 2011
Bictegravir/emtricitabine/tenofovir alafenamide for HIV-1: what is the hidden potential of this emerging treatment?
2023
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women
10.1056/nejmoa2407001 · 2024
Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons
10.1056/nejmoa2411858 · 2025
No additional external references are available.
